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Angiotensinogen has been identified as one of the acute-phase reactants. In vitro studies were carried out using the Reuber 
H35 hepatoma cell line to identify the species of cytokines contributing to the increased synthesis of angiotensinogen 
in the liver. Angiotensinogen secretion by H35 cells was maximally increased 4-fold by the addition of IO-’ M dexameth- 
asone. Under this condition, angiotensinogen secretion was further stimulated by B cell stimulatory factor 2/interleukin-6 
(IL-6,50 U/ml), but not by interleukin-I or interferon-a. In the absence of glucocorticoid, IL-6 did not affect angiotensi- 
nogen secretion by H3.5 cells, indicating that the presence of glucocorticoid is required for the stimulatory activity of 
IL-6. These results suggest that IL-6 is a mediator responsible for the increased synthesis of angiotensinogen in the liver 
during acute inflammation. 
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1. INTRODUCTION 
Angiotensinogen is a plasma glycoprotein, 
predominantly synthesized in the liver, that serves 
as the precursor of the decapeptide angiotensin I
formed by the limited proteolytic action of renin. 
Angiotensin I is further hydrolyzed by a converting 
enzyme to angiotensin II, the biologically active 
molecule that plays an important role in the regula- 
tion of blood pressure [I]. 
Physiological alterations such as volume deple- 
tion and a low-sodium diet, as well as insulin, 
thyroxine, estrogen and glucocorticoid treatment, 
increase the circulating levels of angiotensinogen i
the rat [l-3], and increased levels of angioten- 
sinogen mRNA induced by these hormones have 
been confirmed by in vitro experiments using rat 
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hepatoma or pancreatic islet cell lines [4,5]. In ad- 
dition to these physiological factors, Kageyama et 
al. [6] have demonstrated that the induction of 
acute inflammation in the rat causes a significant 
elevation of the liver angiotensinogen mRNA level. 
Subsequently, we demonstrated that the plasma 
concentration of angiotensinogen was increased in 
rats by the induction of acute inflammation [7]. 
Elevated levels of plasma angiotensinogen have 
also been observed in humans with acute inflam- 
matory diseases [8]. These changes in plasma con- 
centration of angiotensinogen following the induc- 
tion of acute inflammation identify this protein as 
a member of the class of proteins designated 
‘acute-phase reactants’ [9]. Since the acute-phase 
response of angiotensinogen was found in neither 
adrenalectomized [7] nor hypophysectomized rats 
[lo], it was suggested that the rise in plasma 
angiotensinogen under inflammatory conditions is 
secondary to increased adrenocortical secretion. 
However, since no changes in plasma glucocor- 
ticoid level were observed in rats prior to elevation 
of plasma angiotensinogen by lipopolysaccharide- 
induced inflammation [IO], we have suggested that 
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glucocorticoid is not a direct mediator for the 
acute-phase response of angiotensinogen. In addi- 
tion to these findings, we observed that implanta- 
tion of leukocytes collected from rats with acute in- 
flammation caused an elevation of the plasma 
angiotensinogen level in normal rats [lo]. This 
evidence suggests that the acute-phase response of 
angiotensinogen results from increased synthesis of 
angiotensinogen in the liver stimulated by certain 
leukocyte-derived factor(s), and that glucocor- 
ticoid is essential for its stimulatory activity on 
hepatocytes . 
Factors released from leukocytes control many 
of the acute-phase responses. It was found that ac- 
tivated monocytes/macrophages from humans and 
rodents synthesized and released components 
which, when added to cultured hepatocytes, were 
able to induce most of the acute-phase responses in 
plasma protein production [ 1 l-l 31. These activities 
have been attributed to the action of cytokines in- 
cluding hepatocyte-stimulating factor (HSF), 
interleukin-1 (IL-l), tumor necrosis factor and 
interferon-o (IFN-cr) [14-l?‘]. Of these cytokines, 
HSF is known to be a major mediator of the acute- 
phase response [18] and has recently been iden- 
tified as B cell stimulatory factor 2/interleukin-6 
(IL-6) [19,20], originally known as a T cell-derived 
interleukin inducing the final maturation of B cells 
into antibody-forming cells [21,22], IFN&, 
26 kDa protein or hybridoma-plasmacytoma 
growth factor [23]. 
In order to identify and study the mode of action 
of leukocyte-derived factors involved in the acute- 
phase response of angiotensinogen, we used the 
Reuber H35 hepatoma cell line originating from 
the rat, because these cells have been proved to be 
an excellent system for the study of angioten- 
sinogen production and its regulation by glucocor- 
ticoid [4,24]. Here, we demonstrate that IL-6 has 
stimulatory activity on angiotensinogen production 
by H35 cells, and that its effect requires the 
presence of glucocorticoid. 
2. MATERIALS AND METHODS 
2.1. Cytokines 
Human IFN-(r (2 x lo8 IU/mg) and recombinant human 
IL-lo (2 x 10’ U/mg) were donated by Hayashibara Bio- 
chemical Laboratories (Okayama) and Dainippon Phar- 
maceutical (Osaka), respectively. Human recombinant IL-6 
(5.2 x 10 U/mg) was kindly supplied by Drs T. Hirano and T. 
Kishimoto (Institute for Molecular and Cellular Biology, Osaka 
University, Osaka). One unit of the IL-6 preparation was as 
defined by Hirano et al. 121). 
2.2. Purification of angiotensinogen 
Rat plasma angiotensinogen was purified to homogeneity ac- 
cording to Bouhnik et al. [24]. From 260 ml of plasma from 
bilaterally nephrectomized rats, 5.9 mg angiotensinogen was 
finally obtained. The purified angiotensinogen yielded 24.2 pg 
angiotensin I/mg after treatment with hog renin. This is quite 
close to the theoretical value of 22.7 expected for an angioten- 
sinogen with an M, of 57 000. SDS-polyacrylamide gel electro- 
phoresis of the purified preparation gave two protein bands cor- 
responding to M, values of 56000 and 60000, identical to those 
of a homogeneous preparation of rat angiotensinogen reported 
by Hilgenfeldt and Hackenthal 1251. 
2.3. Radioimmunoassay of angiotensinogen 
Angiotensinogen was measured by radioimmunoassay (RIA) 
using ‘2SI-labeled angiotensinogen and rabbit antibody against 
rat angiotensinogen. ‘*‘I-labeled angiotensinogen was prepared 
by the chloramine-T method [26] and separated from free “‘1 
by Sephadex G-SO chromatography. At a dilution of 1: 60000, 
the antiserum bound approx. 40% of the tracer antigen. The 
RIA was carried out in 0.1 M Tris-HCl (pH 7.4), containing 
0.2Vo gelatin and 0.01% neomycin sulfate. The incubation mix- 
ture contained 50 /tl ‘*‘I-angiotensinogen, 50 pl diluted 
(1 :20000) antiserum and 50 ~1 standard (2-500 ng) or sample. 
Following incubation at 4°C for 18 h, tracer that had bound to 
antibody was separated using Zysorbin (Zymed, San Francisco, 
CA) as described [27], and then counted in a gamma-counter. A 
standard curve was obtained by plotting the percentage of initial 
binding against the angiotensinogen standard. A series of dilu- 
tions of culture medium obtained by 48 h culture of H3S cells 
with IO-’ M dexamethasone gave a line parallel with the stan- 
dard curve. Angiotensinogen present in fetal calf serum did not 
cross-react with the antibody. This RIA permitted the detection 
of as little as 10 ng/ml angiotensinogen. 
2.4. Culture experiments 
Reuber H35 cells 1281 were kindly supplied by Dr H. Kawano 
(Kobe-Gakuin University, Kobe), and cultured in 6-well plates 
with Dulbecco’s modified Eagle’s medium (Nissui, Tokyo) con- 
taining 10% fetal calf serum (FCS). The medium was replaced 
by fresh medium every 2 days until cultures approached con- 
fluence. 2 days after reaching confluence, the medium was re- 
placed by one supplemented with 5% FCS depleted of steroid 
hormones (steroid-free medium) 1291. Following 24 h culture, 
the medium was removed and replaced with 2 ml fresh steroid- 
free medium containing cytokines and/or dexamethasone 
(Nacalai Tesque, Kyoto). Cells were then cultured for 24 h, and 
the medium collected in order to assay the amount of secreted 
angiotensinogen. 
3. RESULTS 
Bouhnik and colleagues [24] have demonstrated 
that the Reuber H35 hepatoma cell line produces 
angiotensinogen. According to their procedure, we 
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measured angiotensinogen in culture medium of 
H35 cells by RIA using antibody against rat 
angiotensinogen. The immunological identity of 
the material measured in the culture medium as rat 
angiotensinogen was confirmed by the fact that a 
series of dilutions of the medium gave a displace- 
ment curve parallel with the standard curve for 
purified rat angiotensinogen by RIA. 
The angiotensinogen concentration in the culture 
medium of H35 cells increased linearly for at least 
48 h under either dexamethasone-free or dexa- 
methasone-supplemented (lo-’ M) conditions (not 
shown). Fig.1 shows the amount of angioten- 
sinogen secreted by H35 cells 24 h after the addi- 
tion of several concentrations of dexamethasone. 
Angiotensinogen secretion by H35 cells was in- 
creased by the addition of dexamethasone; max- 
imum response (Cfold) to dexamethasone was ob- 
tained at IO-’ M, half-maximal being at 10e8 M. 
Initial cell number (1.18 x 106/well) increased 
slightly to 1.32 x 106/well after 24 h culture in 
. I I I I I 
0 1o-g lo-* 1 o-7 1o-6 16 
Dexamethasone (M) 
Fig. 1. Secretion of angiotensinogen by H35 cells cultured with 
different concentrations of dexamethasone. H35 cells were 
cultured for 24 h in 2 ml of medium supplemented with dif- 
ferent concentrations of dexamethasone, and angiotensinogen 
secreted into the medium was assayed. Results represent means 
& SD for 4 cultures. Significantly different from the value 
without dexamethasone: *p<O.Ol, **p<O.OOOl. 
dexamethasone-free medium, and the addition of 
10e7 M dexamethasone did not affect cell growth 
(1.29 x 106/well after 24 h culture). 
Cytokines including IL-I, tumor necrosis factor, 
IL-6 and IFN-a have been identified as factors 
responsible for stimulating the hepatic production 
of acute-phase reactants [14-201. In order to ascer- 
tain whether some of these cytokines have 
stimulatory activity on angiotensinogen production 
by H35 cells, cells were cultured for 24 h in the 
presence of dexamethasone (lo-’ M) and several 
concentrations of IL-la, IL-6 or IFN-cz. Tumor 
necrosis factor could not be examined because of 
its cytotoxic activity on the tumor cells. As shown 
in fig.2, angiotensinogen secretion by H35 cells was 
significantly increased by IL-6, but not changed by 
IL-la or IFN-cu. Since the concentration of IL-la 
or IFN-(r would have been sufficient to stimulate 
the hepatic synthesis of other acute-phase reac- 
tants, such as cui-acid glycoprotein by IL-1 in H35 
cells [ 181 and T-kininogen by IFN-cu in primary 
cultured rat hepatocytes [ 171, both cytokines seem- 
ed to be inactive with regard to angiotensinogen 
production by H35 cells. 
Fig.3 shows the dose-response curve obtained 
after treatment of the cells with IL-6 for 24 h in the 
presence or absence of glucocorticoid. In the 
presence of lo-’ M dexamethasone, which pro- 
duced a maximum response of H35 cells (fig.2), 
Cytokines (U/ml) Angiotensinogen (pglwell) 
0 1 2 
Fig.2. Effects of cytokines on the secretion of angiotensinogen 
by H35 cells. IL-la, IL-6 and IFN-cy were added to culture 
medium containing lo-’ M dexamethasone, and H35 cells were 
cultured for 24 h. Concentrations of cytokines are shown. Con- 
trol represents a group cultured with dexamethasone alone. 
Results represent means f SD for 4 cultures. Significantly dif- 
ferent from the values of the control: *p<O.Ol, **p<O.OOl. 
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IL-6 (U/ml) 
Fig.3. Dose response of IL-6-induced secretion of angioten- 
sinogen by H35 cells cultured with different concentrations of 
dexamethasone. H35 cells were cultured in medium sup- 
plemented with several concentrations of IL-6 for 24 h without 
dexamethasone (o), with 10m8 M (A) or 10m7 M dexa- 
methasone (a). Results represent means + SD for 4 cultures. 
Significantly different from the values without IL-6: *p<O.Ol, 
**p<o.O01. 
IL-6 at 50 U/ml further stimulated angiotensi- 
nogen secretion more than 2-fold as compared with 
dexamethasone alone. Dose-dependent stimulation 
of angiotensinogen secretion by IL-6 was also 
observed in the presence of 10e8 M dexametha- 
sone. In contrast, IL-6 was entirely inactive under 
glucocorticoid-free conditions. 
4. DISCUSSION 
The liver has been shown to be the major source 
of plasma angiotensinogen and is therefore impor- 
tant in the regulation of circulating angioten- 
sinogen levels [ 11. Plasma levels of angiotensinogen 
are regulated by a variety of hormones, such as 
glucocorticoid, estrogen and thyroid hormones [ 11. 
Treatment of rats with these hormones increases 
angiotensinogen mRNA levels in the liver and 
other tissues [30]. Bouhnik et al. [24] have 
demonstrated that the Reuber H35 rat hepatoma 
cell line synthesizes angiotensinogen. Chang and 
Perlman [4] have also shown that the angioten- 
sinogen mRNA levels of H35 cells increase follow- 
ing treatment with dexamethasone, aldosterone or 
triiodothyronine. Thus, the H35 cell line is a well- 
defined one for studies on the regulation of 
angiotensinogen synthesis. This was further con- 
firmed in the present study by measuring angioten- 
sinogen secreted from H35 cells. Consistent with 
the results of studies on angiotensinogen mRNA 
levels, angiotensinogen secretion by H35 cells was 
increased 4-fold by lo-’ M dexamethasone, and 
the magnitude of the increase and half-maximal 
concentration of dexamethasone were comparable 
to those reported for the response of angioten- 
sinogen mRNA [4]. 
Using this in vitro system, cytokines including 
IL-l, IL-6 and IFN-a were examined. Of these, 
only IL-6 had potent stimulatory activity; pro- 
duction of angiotensinogen maximally induced by 
IO-’ M dexamethasone was further stimulated by 
50 U/ml IL-6. Interestingly, the presence of gluco- 
corticoid was an absolute requirement for angio- 
tensinogen induction by IL-6. In previous studies, 
we demonstrated that lipopolysaccharide-induced 
acute inflammation does not induce elevation of 
plasma angiotensinogen concentration in adrenal- 
ectomized or hypophysectomized rats [7,10]. Thus, 
the requirement for glucocorticoid of the effect of 
IL-6 observed in vitro is compatible with the 
findings regarding intact animals. It is well known 
that the synthesis of acute-phase reactants in the 
liver requires glucocorticoid [31]. For example, in- 
creases in B-fibrinogen or err-acid glycoprotein 
mRNA levels in rat hepatoma cells produced by 
IL-6 are potentiated by or absolutely dependent 
upon the presence of glucocorticoid 1321. In this 
respect, it appears that IL-6 stimulates the hepatic 
synthesis of angiotensinogen by a mechanism 
similar to that which regulates the synthesis of 
other acute-phase reactants. 
IL-6 has recently been recognized as a major 
mediator of the acute-phase response [19,20], in- 
dicating that its action is not restricted to the im- 
mune system. The recent findings that HSF (IL-6) 
and IL-1 stimulate pituitary cells to release adreno- 
corticotropic hormone [33,34] suggest that 
molecules involved in the immune system can also 
control neuroendocrine functions. To our 
knowledge, the present study is the first to provide 
evidence that a mediator involved in immune func- 
9 
Volume 244, number 1 FEBS LETTERS February 1989 
tion can modulate the function of the renin- 
angiotensin system. Many investigators have ob- 
tained data suggesting that, in addition to the renin 
concentration in plasma, the plasma level of 
angiotensinogen is a rate-limiting factor in the 
generation of angiotensin I and ultimately impor- 
tant in the regulation of blood pressure [1,3]. In 
fact, we have found that the level of angiotensin I
generation is high in plasma obtained from rats 
with acute inflammation [35]. Therefore, the 
evidence provided here may also be further in- 
dicative of communication between the immune 
and endocrine systems. 
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